Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, OntarioDr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.
Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.
Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.
Disclosures
- Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics
Recent Contributions to PracticeUpdate:
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
- NT-proBNP and Cardiovascular Event Risk in Individuals With Prediabetes Undergoing Cardiovascular Evaluation
- Intensive Statin Therapy vs Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome
- Calcium Channel Blocker Use and Associated Glaucoma and Related Traits Among UK Biobank Participants
- Pillars of Therapy to Slow Diabetic Nephropathy Progression
- Estimated Lifetime Gained With Cancer Screening Tests
- Prevalence and Predictors of Primary Nonadherence to Medications Prescribed in Primary Care
- Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas in Reducing the Risk of Major Adverse Cardiovascular Events
- Dupilumab for Patients With COPD With Type 2 Inflammation Indicated by Eosinophil Counts
- Association of Exposure to Extreme Temperature Events and Fine Particulate Matter With Myocardial Infarction–Related Mortality